Australian (ASX) Stock Market Forum

OCC - Orthocell Limited

Jump to new
Income from Striate+ and Remplir sales now being received.

Two newly elected high profile Non Executive Directors in Professor Fiona Woods and Kim Beasley should improve the companies recognition in international markets.
 
Still slowly developing.

I would have liked one of their treatment (awaiting approval) when I was younger - a non-surgical treatment for tennis elbow.
 
Chart update only.

1709190404627.png
 
access said:
Income from Striate+ and Remplir sales now being received.

Two newly elected high profile Non Executive Directors in Professor Fiona Woods and Kim Beasley should improve the companies recognition in international markets.
Click to expand...
Kim Beasley.
.. is there an emoji that is appropriate?
 
I would expect Kim is on the Board to draw on experience and connections from his days as Australian Ambassador in America from 2010 to 2016. Would have a lot of connections and understanding of how business works in American.

Remplir could be approved in America at the end of this year.
 
April update: Qrtly report. Increasing revenue of 1.61M in Q3 (+19% Q3-23).
Completes $3.5M placement, holds $20M cash.

Results of Remplir US market authorisation study to be released Q3 - 24.

Chart perspective, price remains in sideways range that's lasted 2.5yrs.
 
Continuing to expand with new registration applications and extending approval applications for existing products into new markets worldwide
 
Of OCC's 7 products, 2 are on the market and another one is expected to be released next year.

Petra Capital this month have a Target Price of $1.28 (current price .425 cents).
 
Institutions are now starting to notice OCC. Company put to the market a placement for $12 million at .60 cents but the offer was oversubscribed by another $5 million to $17 million.

Company now has cash of $35 million to fund release of Remplir in the USA and other countries around the world.
 
Top